Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.
about
Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancyThe anti-tumor effect of HDAC inhibition in a human pancreas cancer model is significantly improved by the simultaneous inhibition of cyclooxygenase 2Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expressionAutophagic and apoptotic effects of HDAC inhibitors on cancer cellsVorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.Histone deacetylase inhibitors interact with melanoma differentiation associated-7/interleukin-24 to kill primary human glioblastoma cells.Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancerCombining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cellsA novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance.Emerging therapeutic targets for soft tissue sarcoma.HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.The anti-tumor activity of E1A and its implications in cancer therapy.Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells.Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals.Synergistic anticancer activity of valproate combined with nicotinamide enhances anti-proliferation response and apoptosis in MIAPaca2 cells.The enhanced apoptosis and antiproliferative response to combined treatment with valproate and nicotinamide in MCF-7 breast cancer cells.Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancerDNMT inhibitors and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo.Early prediction of response to Vorinostat in an orthotopic rat glioma model.Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells.Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells.Epigenetic approaches for chemosensitization of refractory diffuse large B-cell lymphomas.The in vitro apoptotic effects of A248 and A1659, newly synthetic histone deacetylase inhibitors in oral cancer cells.Growth-suppressive effect of suberoylanilide hydroxamic acid (SAHA) on human oral cancer cells.Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action.
P2860
Q28082536-AF25FD11-3C7B-44D2-BE65-64DA9CD21778Q28533258-22C5F95B-31B8-47A4-B29C-79C8E11C1673Q28743074-136A859C-3070-48C7-B8C3-90DA17048E70Q35001459-8D627D16-D962-4803-82B5-99F6E4AE91FEQ36501207-3E226E16-B155-413E-A17E-363B8E16CF74Q37013055-B1EDC5C9-07BB-44F9-A277-356C5B096020Q37027060-2486EC90-89A4-48A4-9320-EF78B1989C38Q37092508-D17FCB62-858B-4FBB-B9B7-60CD6CDD2052Q37586906-C5792CD6-2B01-450E-9E3A-DB2A952C253AQ37612692-6606E5A5-01C6-4B56-BE5C-DA0CC653AC1CQ37869364-DDCB5B18-6CCF-4EC3-ADC2-5B29B72D583CQ37993586-916C590C-E809-4224-9B90-183099BEE23EQ38185905-64EC60E4-B610-48CF-B2C2-84379E546223Q38674753-3B7F1BF1-D24E-47BE-8194-BF3C7CAC798AQ38816103-FC536BEE-72B8-48A2-A25C-E7D8DCA4BB0BQ39018558-0F6B5D42-32EA-49F1-AFEE-52B658959907Q39064829-98CB0BC0-9E57-4E10-A7B9-5946AD3A8112Q39069931-B8FD75DA-3E7B-4F66-AAF8-C2E779AB5484Q39395099-AB9A1C21-B685-4CFC-96E8-E9340D777149Q39402126-E832D496-F361-4BE2-A878-8EFDD874BE06Q39434896-35397345-DBFF-414A-9D1F-1CF637AE4E72Q40468248-EDF6A53F-CA82-4049-B2E9-BF3D24DCC7F6Q42098536-DBC2D394-9C8C-4816-AD9C-A50A696BBB37Q43970077-48643B1A-D22E-42F5-AF64-7B25E8704607Q52901914-E772732D-5F20-4FAC-872B-DD8D1F4192A5Q53143241-38EF8048-F59D-481E-AA91-EDC0E2900C04
P2860
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Histone Deacetylase Inhibitors ...... ogical and Solid Malignancies.
@ast
Histone Deacetylase Inhibitors ...... ogical and Solid Malignancies.
@en
Histone Deacetylase Inhibitors ...... ogical and Solid Malignancies.
@nl
type
label
Histone Deacetylase Inhibitors ...... ogical and Solid Malignancies.
@ast
Histone Deacetylase Inhibitors ...... ogical and Solid Malignancies.
@en
Histone Deacetylase Inhibitors ...... ogical and Solid Malignancies.
@nl
prefLabel
Histone Deacetylase Inhibitors ...... ogical and Solid Malignancies.
@ast
Histone Deacetylase Inhibitors ...... ogical and Solid Malignancies.
@en
Histone Deacetylase Inhibitors ...... ogical and Solid Malignancies.
@nl
P2860
P356
P1433
P1476
Histone Deacetylase Inhibitors ...... ogical and Solid Malignancies.
@en
P2093
Leigh Ellis
Roberto Pili
P2860
P304
P356
10.3390/PH3082441
P577
2010-08-01T00:00:00Z